Lenalidomide Glenmark (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4‑CRBN E3 ubiquitin ligase complex, leading to the targeted degradation of transcription factors Ikaros and Aiolos. This results in modulation of the immune system, inhibition of angiogenesis, and direct anti‑proliferative and pro‑apoptotic effects on malignant plasma cells and myeloid progenitors.

The specific dose of Lenalidomide Glenmark is determined by the prescribing physician based on the patient’s diagnosis, disease stage, renal function, and prior therapies. Dosing regimens are individualized and should follow the latest clinical guidelines and the product’s prescribing information.

Lenalidomide is classified as Pregnancy Category X because it is highly teratogenic and can cause fetal harm. It is contraindicated in pregnancy, and effective contraception must be used by both male and female patients of reproductive potential. Use during breastfeeding is not recommended as the drug may be excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the sales team provides pricing, availability, shipping details (including any cold‑chain requirements), and assists with import documentation.

Lenalidomide belongs to the immunomodulatory drug class, offering a distinct mechanism compared with proteasome inhibitors or monoclonal antibodies. It provides oral administration, which can be more convenient than injectable therapies, and is often combined with dexamethasone or other agents to enhance efficacy. Choice of therapy depends on disease characteristics, prior treatment exposure, and patient tolerance.

Lenalidomide Glenmark should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date printed on the label.

Lenalidomide Glenmark is taken orally, usually as a tablet, with or without food as directed by the prescriber. The medication is swallowed whole with a glass of water, and the dosing schedule (e.g., daily for a set number of days followed by a rest period) is individualized based on the treatment protocol.

The most serious risks include severe neutropenia and thrombocytopenia, which can lead to infections or bleeding, and an increased risk of venous thromboembolism such as deep‑vein thrombosis or pulmonary embolism. Additionally, Lenalidomide is teratogenic, and rare cases of secondary malignancies have been reported. Patients should be monitored closely for these events.

Lenalidomide Glenmark should not be used by individuals who are pregnant, planning to become pregnant, or not using effective contraception. Patients with uncontrolled infections, severe renal impairment (unless dose‑adjusted), or known hypersensitivity to lenalidomide or any of its excipients should avoid the drug. Clinicians must evaluate each patient’s medical history before initiating therapy.